Sartorius Reports Strong Start in 2025 First Quarter

Sartorius AG, based in Göttingen, Germany, has announced a robust first quarter in 2025, showing a 6.5% increase in group sales revenue. The company attributes this growth primarily to a strong demand for consumables in its Bioprocess Solutions division, which saw revenue growth close to 10%. In contrast, the lab division faced muted development as anticipated.

The company achieved an overproportional rise in underlying EBITDA, increasing by 12.2% to 263 million euros, with margins reaching 29.8%. Order intake exceeded sales revenue, resulting in a favorable book-to-bill ratio above one. Sartorius anticipates a 6% growth in sales revenue for the year, maintaining an EBITDA margin between 29% and 30%.

Across regions, sales revenue growth was positive, led by an 8.1% increase in the Americas. Despite challenges, Sartorius continues to focus on the burgeoning demand for biologics, supporting innovative technologies for efficient biopharmaceutical production.